Reuters logo
in 3 months
BRIEF-pSivida announces positive 12-month follow-up data for Durasert three-year treatment for posterior segment uveitis
May 8, 2017 / 1:21 PM / in 3 months

BRIEF-pSivida announces positive 12-month follow-up data for Durasert three-year treatment for posterior segment uveitis

1 Min Read

May 8 (Reuters) - Psivida Corp

* Psivida corp- durasert™ three-year treatment for posterior segment uveitis significantly reduces recurrences through 12 months

* Psivida corp- psivida anticipates reporting top line results from second pivotal phase 3 clinical trial in june 2017

* Psivida corp- announced 12-month follow-up data for company's durasert three-year treatment for posterior segment uveitis Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below